Defining neuroblastoma : From origin to precision medicine
(2024) In Neuro-Oncology 26(12). p.2174-2192- Abstract
Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies as potential approaches for improving the survival and quality of life of children with... (More)
Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies as potential approaches for improving the survival and quality of life of children with NB.
(Less)
- author
- Sainero-Alcolado, Lourdes ; Sjöberg Bexelius, Tomas ; Santopolo, Giuseppe ; Yuan, Ye ; Liaño-Pons, Judit and Arsenian-Henriksson, Marie LU
- organization
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- immunotherapy, neural differentiation, neuroblastoma, sympathoadrenal development, targeted therapies
- in
- Neuro-Oncology
- volume
- 26
- issue
- 12
- pages
- 19 pages
- publisher
- Oxford University Press
- external identifiers
-
- scopus:85212457240
- pmid:39101440
- ISSN
- 1523-5866
- DOI
- 10.1093/neuonc/noae152
- language
- English
- LU publication?
- yes
- id
- f208c8ee-d8fa-4d2f-b027-af88e09ab21a
- date added to LUP
- 2025-01-17 12:03:50
- date last changed
- 2025-05-23 22:46:35
@article{f208c8ee-d8fa-4d2f-b027-af88e09ab21a, abstract = {{<p>Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies as potential approaches for improving the survival and quality of life of children with NB.</p>}}, author = {{Sainero-Alcolado, Lourdes and Sjöberg Bexelius, Tomas and Santopolo, Giuseppe and Yuan, Ye and Liaño-Pons, Judit and Arsenian-Henriksson, Marie}}, issn = {{1523-5866}}, keywords = {{immunotherapy; neural differentiation; neuroblastoma; sympathoadrenal development; targeted therapies}}, language = {{eng}}, number = {{12}}, pages = {{2174--2192}}, publisher = {{Oxford University Press}}, series = {{Neuro-Oncology}}, title = {{Defining neuroblastoma : From origin to precision medicine}}, url = {{http://dx.doi.org/10.1093/neuonc/noae152}}, doi = {{10.1093/neuonc/noae152}}, volume = {{26}}, year = {{2024}}, }